Health Condition 1: J449- Chronic obstructive pulmonary disease, unspecified
Conditions
Interventions
Intervention1: Glycopyrrolate, Formoterol Fumarate and Budesonide Inhalation
9 mcg, 4.8 mcg and 160 mcg: All patients will be asked to take two inhalations of
Glycopyrrolate, Formoterol Fumarate and
Sponsors
Zydus Healthcare Limited
Clinical Research Network India CRO
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients of either sex between 40-65 years of age (both inclusive) 2. Patients who are current/ex-smokers 3. Patients diagnosed with moderate to severe COPD as per the GOLD guidelines classification at screening visit: o Post-bronchodilator FEV1/FVC ratio o Post-bronchodilator FEV1, = 30% to 4. COPD Assessment Test (CATTM) score = 10 even after receiving at least two inhaled maintenance therapies (LABA+ LAMA or LABA + ICS) for at least 4 weeks at the time of screening 5. Written informed consent from the patient 6. Patients literate enough to fill the diary card and willing to comply with the protocol requirements
Exclusion criteria
Exclusion criteria: 1. Patients suffering from other lung disorders such as but not limited to asthma, active tuberculosis, bronchiectasis, interstitial lung disease, lung cancer etc. 2. Patients with known a1 antitrypsin deficiency 3. Patients diagnosed with COVID-19 in last 3 months 4. COPD exacerbation that requires treatment with systemic corticosteroids or antibiotics within 4 weeks prior to screening or during the screening period 5. Patients hospitalized for COPD exacerbation within 3 months prior to the screening visit or during the screening period 6. Respiratory tract infections that required antibiotics within 4 weeks prior to the screening or during the screening period 7. Patients who required long-term oxygen therapy (=12hours/day) within 4 weeks prior to the screening or during the screening period 8. Patients with known diagnosis of narrow angle glaucoma, prostatic hyperplasia, bladder-neck obstruction or urinary retention 9. Patients with known hypersensitivity to formoterol, glycopyrronium, salbutamol, other beta-2 agonists or other anti-muscarinic agents 10. Patients with clinically significant uncontrolled systemic diseases such as cardiovascular, renal, neurological, psychiatric, endocrine, immunological or hematological disorders or malignancy 11. Patients with hepatic dysfunction (serum transaminases = 3 x Upper Normal Limit) or renal dysfunction (serum creatinine = 2.5 mg/dl) at screening 12. Patients with continuing history of alcohol and/or drug abuse 13. Pregnant or Lactating females; or female patients of childbearing potential unwilling to use effective contraception 14. Participation in another clinical trial in the past 3 months 15. Any other reason for which the investigator feels that the patient should not participate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in trough FEV1 at week 4 and week 12 as compared to baselineTimepoint: week 4 and 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| ? Change in CATTM score at week 4, 8 and 12 as compared to baseline ? Change in trough FVC at week 4 and week 12 as compared to baseline ? Change in post-bronchodilator FEV1 and FVC at week 4 and week 12 as compared to baseline ? Responder rate at week 4 and week 12 ? Rescue bronchodilator use during treatment period ? Proportion of patients with COPD exacerbations during the study Safety endpoints will be: ? Adverse events reported during the study ?Serious adverse events reported during the study Timepoint: week 4, 8 and 12. | — |
Countries
India
Contacts
Public ContactDr Jayesh Sanmukhani
Zydus Healthcare Limited
Outcome results
None listed